RA Capital Management - Q3 2023 holdings

$5.08 Billion is the total value of RA Capital Management's 66 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 29.6% .

 Value Shares↓ Weighting
ASND SellASCENDIS PHARMA A/S - ADR$1,003,779,130
+0.2%
10,719,555
-4.5%
19.76%
+4.5%
LEGN  LEGEND BIOTECH CORP-ADR$420,800,369
-2.7%
6,264,7070.0%8.28%
+1.5%
PCVX  VAXCYTE INCsponsored ads$402,296,129
+2.1%
7,891,2540.0%7.92%
+6.4%
IMGN BuyIMMUNOGEN INC$211,424,711
+380.9%
13,322,288
+471.8%
4.16%
+401.4%
ETNB  89BIO INC$176,277,677
-18.5%
11,416,9480.0%3.47%
-15.1%
BIIB  BIOGEN INCsponsored adr$136,958,573
-9.8%
532,8920.0%2.70%
-5.9%
RYTM  RHYTHM PHARMACEUTICALS INC$130,123,836
+39.0%
5,676,0670.0%2.56%
+45.0%
AVTE  AEROVATE THERAPEUTICS INC$112,142,236
-20.9%
8,263,9820.0%2.21%
-17.5%
CBAY NewCYMABAY THERAPEUTICS INC$103,475,4006,940,000
+100.0%
2.04%
VRNA  VERONA PHARMA PLC - ADR$102,983,237
-22.9%
6,317,9900.0%2.03%
-19.6%
 TYRA BIOSCIENCES INC$99,645,972
-19.1%
7,236,4540.0%1.96%
-15.7%
WVE  WAVE LIFE SCIENCES LTD$98,911,552
+58.0%
17,202,0090.0%1.95%
+64.7%
GERN BuyGERON CORP$97,949,141
-3.3%
46,202,425
+46.5%
1.93%
+0.8%
DAWN  DAY ONE BIOPHARMACEUTICALS I$95,826,884
+2.8%
7,809,8520.0%1.89%
+7.1%
JANX BuyJANUX THERAPEUTICS INC$92,389,772
-10.2%
9,165,652
+5.7%
1.82%
-6.4%
BuyAN2 THERAPEUTICS INC$89,264,824
+178.3%
5,551,295
+47.1%
1.76%
+189.9%
INBX BuyINHIBRX INCsh$86,689,198
-13.4%
4,724,207
+22.6%
1.71%
-9.6%
 RXSIGHT INC$85,142,480
-3.2%
3,052,7960.0%1.68%
+1.0%
 NEWAMSTERDAM PHARMA CO NV$83,250,000
-22.2%
9,000,0000.0%1.64%
-18.9%
EVH NewEVOLENT HEALTH INC - A$74,519,7962,736,680
+100.0%
1.47%
CVAC SellCUREVAC NV$72,427,670
-43.2%
10,604,344
-13.4%
1.43%
-40.8%
AXSM  AXSOME THERAPEUTICS INC$69,890,000
-2.7%
1,000,0000.0%1.38%
+1.4%
COGT  COGENT BIOSCIENCES INC$62,557,433
-17.7%
6,416,1470.0%1.23%
-14.1%
ABOS BuyACUMEN PHARMACEUTICALS INC$61,968,061
+31.9%
14,932,063
+52.8%
1.22%
+37.5%
TSHA NewTAYSHA GENE THERAPIES INC$58,373,10918,472,503
+100.0%
1.15%
GHRS  GH RESEARCH PLCsponsored adr$56,152,697
-15.3%
5,587,3330.0%1.10%
-11.7%
ALPN  ALPINE IMMUNE SCIENCES INC$53,713,988
+11.4%
4,691,1780.0%1.06%
+16.0%
FDMT Buy4D MOLECULAR THERAPEUTICS IN$52,997,676
-4.5%
4,163,211
+35.6%
1.04%
-0.4%
FULC  FULCRUM THERAPEUTICS INC$51,547,086
+34.5%
11,609,7040.0%1.02%
+40.4%
ITOS  ITEOS THERAPEUTICS INC$48,368,986
-17.3%
4,417,2590.0%0.95%
-13.8%
VOR  VOR BIOPHARMA INC$48,227,626
-31.4%
22,748,8800.0%0.95%
-28.5%
 ICOSAVAX INC$46,217,629
-22.0%
5,963,5650.0%0.91%
-18.6%
 ACRIVON THERAPEUTICS INC$45,988,456
-26.2%
4,810,5080.0%0.90%
-23.1%
NewAPOGEE THERAPEUTICS INC$42,129,2911,977,901
+100.0%
0.83%
 PEPGEN INC$41,310,316
-43.2%
8,131,9520.0%0.81%
-40.8%
RNA  AVIDITY BIOSCIENCES INC$40,940,447
-42.5%
6,416,9980.0%0.81%
-40.0%
SellCYTEK BIOSCIENCES INC$37,587,910
-64.2%
6,809,404
-44.6%
0.74%
-62.7%
NewSOLENO THERAPEUTICS INC$36,562,8901,239,000
+100.0%
0.72%
SBTX BuyARS PHARMACEUTICALS INC$35,757,583
+77.3%
9,459,678
+214.3%
0.70%
+84.8%
 ELIEM THERAPEUTICS INCads$34,586,733
-6.1%
13,150,8490.0%0.68%
-2.0%
VRDN  VIRIDIAN THERAPEUTICS INC$30,801,892
-35.5%
2,007,9460.0%0.61%
-32.8%
PLRX  PLIANT THERAPEUTICS INC$30,553,080
-4.3%
1,762,0000.0%0.60%
-0.3%
 MINERALYS THERAPEUTICS INC$30,227,307
-44.2%
3,178,4760.0%0.60%
-41.8%
ACRS  ACLARIS THERAPEUTICS INCsponsored ads$30,129,403
-33.9%
4,398,4530.0%0.59%
-31.1%
MDGL NewMADRIGAL PHARMACEUTICALS INC$29,865,180204,500
+100.0%
0.59%
 ENLIVEN THERAPEUTICS INC$28,992,872
-33.1%
2,122,4650.0%0.57%
-30.2%
EYPT  EYEPOINT PHARMACEUTICALS INC$26,930,343
-8.2%
3,370,5060.0%0.53%
-4.3%
URGN NewUROGEN PHARMA LTD$20,786,5951,483,697
+100.0%
0.41%
BuyTENAYA THERAPEUTICS INC$17,132,132
-51.9%
6,718,483
+10.7%
0.34%
-49.9%
BCYC NewBICYCLE THERAPEUTICS PLC-ADRsponsored adr$16,072,000800,000
+100.0%
0.32%
HOWL  WEREWOLF THERAPEUTICS INC$13,150,045
-29.8%
6,144,8810.0%0.26%
-26.8%
CELC  CELCUITY INC$12,796,009
-16.8%
1,400,0010.0%0.25%
-13.1%
NKTR NewNEKTAR THERAPEUTICS$11,137,72018,700,000
+100.0%
0.22%
NKTX  NKARTA INC$10,849,129
-36.5%
7,805,1290.0%0.21%
-33.7%
BDTX  BLACK DIAMOND THERAPEUTICS I$10,118,914
-43.2%
3,525,7540.0%0.20%
-40.8%
CMPS NewCOMPASS PATHWAYS PLC$9,516,4001,286,000
+100.0%
0.19%
 SOLID BIOSCIENCES INC$8,634,241
-51.9%
3,426,2860.0%0.17%
-49.9%
IGMS  IGM BIOSCIENCES INC$7,828,125
-9.5%
937,5000.0%0.15%
-5.5%
TALS BuyTALARIS THERAPEUTICS INC$6,753,099
-4.8%
2,403,238
+3.0%
0.13%
-0.7%
CMRX NewCHIMERIX INC$6,240,2596,501,624
+100.0%
0.12%
NewTHIRD HARMONIC BIO INC$6,146,305961,863
+100.0%
0.12%
CNTB  CONNECT BIOPHARMA HOLDINGS L$5,725,631
-27.5%
6,991,0030.0%0.11%
-24.2%
NewUNICYCIVE THERAPEUTICS INC$2,984,7923,470,688
+100.0%
0.06%
NSTG  NANOSTRING TECHNOLOGIES INCordinary shares$2,964,202
-57.5%
1,723,3730.0%0.06%
-56.1%
MGNX NewMACROGENICS INC$1,593,720342,000
+100.0%
0.03%
 NEWAMSTERDAM PHARMA CO NV-27$633,333
-9.1%
333,3330.0%0.01%
-7.7%
DSGN ExitDESIGN THERAPEUTICS INC$0-2,971,231
-100.0%
-0.35%
ExitDICE THERAPEUTICS INC$0-7,856,612
-100.0%
-6.89%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
  • View 13F-HR/A filed 2023-11-15
About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%
ARYA Sciences Acquisition Corp VSold outMay 15, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-12
SC 13G2024-04-12
SC 13D/A2024-04-11
SC 13G2024-04-11
42024-04-04
SC 13G2024-04-04
SC 13G2024-04-01
42024-03-29
SC 13D/A2024-03-29
SC 13D/A2024-03-29

View RA Capital Management's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been amended

Export RA Capital Management's holdings